ASCO 2025

Practice changing results for EBC patients?

WSG: HER2+ pooled analysis

HRD and BRCA status as a new innovative staging system?

TRADE: Abemaciclib in eBC

Risk according to NATALEE / MonarchE in WSG-ADAPT trial

Triple therapy 1st line | double therapy 2nd line - new…

AI and ADCs: Precision diagnostics & safer rechallenge…

Next-gen endocrine therapies and ADCs: Updates from…

SERENA-6 - a challenging strategy?

A new standard for the firstline treatment of HER2+…

A new standard for endocrine-resistant HR+ MBC?

SG + Pembro in aTNBC: a new standard of care?

Additional chemo-free option for TNBC

ASCENT-04

Additional ADC effective for untreated TNBC

New treatment option in first line of metastatic TNBC

Effective ADC for HER2+ mBC with brain metastases

Ipataserib + Fulvestrant improves PFS in PIK3CA-altered…

T-DXd: Detecting ILD and treat again

A new first-line therapy for TNBC

SG + Pembrolizumab might become SOC for PD-L1-positive…

Vepdegestrant for treatment of ER+/HER2- aBC

New firstline SOC for HER2+ metastatic BC

Final OS-Analysis of INAVO-120 trial

ABC for metastatic TNBC

New AKT/PIK3 Antagonist for treatment of mBC after…

Liquid biopsy as a navigator for personalized therapy…

Sac-TMT for metastatic TNBC

Future new SOC for PD-L1-positive mTNBC

Re-exposition and ILD

Nuovo antagonista di AKT/PIK3 per il trattamento della…

SG + Pembrolizumab podría convertirse en el tratamiento…

Ipatasertib + Fulvestrant mejora la supervivencia libre…

Una nuova terapia di prima linea per il TNBC

Un nouveau traitement de première ligne pour le TNBC

Vepdegestrant per il trattamento di ER+/HER2- aBC

Analisi finale della OS dello studio INAVO-120

PARP-inhibitor combinations in advanced prostate cancer

The role of ARPIs in mHSPCThe role of ARPIs in mHSPC

Stereotactic beam radiation therapy 2.0

Niraparib + Abiraterone Improves Outcomes in…

Adding EZH2 to Enzalutamide to decrease the development…

New way of treatment for PCa

Localized CSPC - innovations

Immuntherapy - an evolution?

Real world data from ironman registry confirms…

News of ANZUP trial

mHSPC - prognostification - indications on integration?

mHSPC - ADT + NHT updates

Combination of LU-PSMA and immunotherapy, EVOLUTION…

Rebirth of Rucaparib

CAN-2409 Offers First New Option in 20 Years

Personalized In Situ Immunotherapy SYNC-T Shows High…

Real-world data från Ironman: PSA nivå en viktig…

Evolution: Kombination av LuPSMA och immunterapi.

Sasanlimab + BCG: Practice-Changing Potential for…

ICI Combos in 1L and Maintenance – Mixed Bags or…

ctDNA Clearance Confirms Added Value of Perioperative…

UTUC - enlighted

Benefit of IO/IO therapy in mUC

The role of sansalimab (+ SG) in BCG-naive and…

mUC EVP + subsequent therapies

New nectin-4 ADCs are coming

mUC - new approaches?

Intensive caution of BCG Therapy

ASCO 2025 - Highlights for Bladder Cancer

New option for high-risk NMIBC

CREST Study: Promising Results with PD-1 Inhibitor…

Update on EV-PEM in the EV-302 study

Response matters in advanced urothelial cancer patients…

A new prognostic factor in bladder cancer?: The case of…

El rol de sansalimab (+ SG) en el carcinoma urotelial…

ASCO 2025 - Στιγμιότυπα για τον καρκίνο της ουροδόχου…

¿Un nuevo factor pronóstico en el cáncer de vejiga? El…

De nouveaux ADC pour la nectine-4 arrivent

La respuesta es importante en pacientes con cáncer…

Casdatifan + Cabo – Too Early to Call It a Game…

9 Years of CheckMate 214 – Is Nivo + Ipi Still Holding…

PDIGREE: Real-Life Answers for Post-Ipi/Nivo Decisions

HIF alpha still an interesting target in RCC and other…

Allogeneic CD70 CAR T Cells in refractory RCC

5-Year OS data from the KEYNOTE-564 study

Long-term outcome of Nnivo-Ipi in clear cell RCC

Zanzalitinib + Nivolumab +/- Relatlimab in Front-line…

Nivo + Ipi - Update & Insights

Neoadjuvant Approaches in resectable NSCLC: Insights…

MRD-analysis of the AEGEAN-trial

Chemoimmunotherapy followed by chemoradiotherapy

Neoadjuvant Alectinib in resectable stage III NSCLC

ctDNA stratification

CM-816: The OS results are positive and demonstrate…

Neadjuvant targeted therapy

cTDNA in periop chemo-IO strategies

CheckMate 816: Update on OS-benefit

CheckMate 816 : Mise à jour sur les avantages du…

CM-816 : Les résultats de l'OS sont positifs et…

Targeting rare mutations in metastatic NSCLC - HER2 and…

What is the future in the field of EGFR resistance?

Time of day of immunotherapy is important

RELA-104-biomarker-analysis

HERTHENA-Lung02 unfortunately negative study -…

Is there still a place for HER3-DXd in advanced NSCLC?

HER3-DXd: dissapointing negative trial

GDPase-Inhibition 1st line in KRAS G12C Mut.: Improved…

KRAS G12C: Can immunotherapy improve patient outcome…

ADC in the 3L beats docetaxel

TROP2 targets – where is first-line development…

Sevarbertinib – an additional option for HER2 exon 20…

Have we MET our target?

Does the timing of IO-infusion impact survival?

Benefit of IO is depending on the time of day of…

Updates on ADCs in EGFR resistance

Immunotherapy – before or after 3 p.m.?

Hebben we ons doel gehaald?

HERTHENA-Lung02 étude malheureusement négative -…

Actualizaciones sobre los ADC en la resistencia al EGFR

Is er nog een plaats voor HER3-DXd in gevorderd NSCLC?

The first positive maintenance therapy in SCLC

DeLLphi-304: Dramatic change in 2L-treatment in SCLC

Taralatamb - the new SOC in 2L treatment

New maintenance therapy for SCLC

Tarlatamab - a new SOC in second line

De nouvelles thérapies pour améliorer la survie des…

LA HNSCC - New neoadjuvant SOC